Ocugen annual revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ocugen Revenue Growth & History (OCGN)
Ocugen reported $4.4M in revenue for fiscal 2025, an increase of 8.83% from the previous fiscal year.
View full Ocugen company overviewOcugen annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.4M | $358,000 | +8.83% |
| 2024 | 2024-12-31 | $4.1M | −$2.0M | −32.82% |
| 2023 | 2023-12-31 | $6.0M | $3.5M | +142.60% |
| 2022 | 2022-12-31 | $2.5M | $2.5M | — |
| 2021 | 2021-12-31 | $0 | −$43,000 | −100.00% |
| 2020 | 2020-12-31 | $43,000 | $43,000 | — |
| 2019 | 2019-12-31 | $0 | $0 | — |
| 2018 | 2018-12-31 | $0 | $0 | — |
| 2017 | 2017-12-31 | $0 | $0 | — |
| 2016 | 2016-12-31 | $0 | $0 | — |
| 2015 | 2015-12-31 | $0 | $0 | — |
| 2014 | 2014-12-31 | $0 | — | — |
Ocugen quarterly revenue
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q2.20
Q3.20
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.5M | $115,000 | +8.38% |
| Q1 2026 | 2026-03-31 | $1.5M | $52,000 | +3.51% |
| Q4 2025 | 2025-12-31 | −$193,000 | −$957,000 | −125.26% |
| Q3 2025 | 2025-09-30 | $1.8M | $616,000 | +54.23% |
| Q2 2025 | 2025-06-30 | $1.4M | $232,000 | +20.33% |
| Q1 2025 | 2025-03-31 | $1.5M | $467,000 | +46.06% |
| Q4 2024 | 2024-12-31 | $764,000 | −$645,000 | −45.78% |
| Q3 2024 | 2024-09-30 | $1.1M | −$2.6M | −69.29% |
| Q2 2024 | 2024-06-30 | $1.1M | $656,000 | +135.26% |
| Q1 2024 | 2024-03-31 | $1.0M | $571,000 | +128.89% |
| Q4 2023 | 2023-12-31 | $1.4M | $530,000 | +60.30% |
| Q3 2023 | 2023-09-30 | $3.7M | $3.2M | +693.78% |
| Q2 2023 | 2023-06-30 | $485,000 | −$158,000 | −24.57% |
| Q1 2023 | 2023-03-31 | $443,000 | −$57,000 | −11.40% |
| Q4 2022 | 2022-12-31 | $879,000 | — | — |
| Q3 2022 | 2022-09-30 | $466,000 | $466,000 | — |
| Q2 2022 | 2022-06-30 | $643,000 | $643,000 | — |
| Q1 2022 | 2022-03-31 | $500,000 | — | — |
| Q3 2021 | 2021-09-30 | $0 | $0 | — |
| Q2 2021 | 2021-06-30 | $0 | −$43,000 | −100.00% |
| Q3 2020 | 2020-09-30 | $0 | $0 | — |
| Q2 2020 | 2020-06-30 | $43,000 | $43,000 | — |
| Q4 2019 | 2019-12-31 | $0 | $0 | — |
| Q3 2019 | 2019-09-30 | $0 | $0 | — |
| Q2 2019 | 2019-06-30 | $0 | $0 | — |
| Q1 2019 | 2019-03-31 | $0 | $0 | — |
| Q4 2018 | 2018-12-31 | $0 | $0 | — |
| Q3 2018 | 2018-09-30 | $0 | $0 | — |
| Q2 2018 | 2018-06-30 | $0 | $0 | — |
| Q1 2018 | 2018-03-31 | $0 | $0 | — |
| Q4 2017 | 2017-12-31 | $0 | $0 | — |
| Q3 2017 | 2017-09-30 | $0 | $0 | — |
| Q2 2017 | 2017-06-30 | $0 | $0 | — |
| Q1 2017 | 2017-03-31 | $0 | $0 | — |
| Q4 2016 | 2016-12-31 | $0 | $0 | — |
| Q3 2016 | 2016-09-30 | $0 | $0 | — |
| Q2 2016 | 2016-06-30 | $0 | $0 | — |
| Q1 2016 | 2016-03-31 | $0 | $0 | — |
| Q4 2015 | 2015-12-31 | $0 | — | — |
| Q3 2015 | 2015-09-30 | $0 | — | — |
| Q2 2015 | 2015-06-30 | $0 | — | — |
| Q1 2015 | 2015-03-31 | $0 | — | — |
Ocugen revenue growth trends
Over the last five reported fiscal years, revenue grew from $43,000 to $4.4M, a compound annual growth rate of 152.50%. Ocugen's latest reported quarter, Q2 2026, generated $1.5M in revenue, an increase of 8.38% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Ocugen source filings ↗Community posts
Ocugen receives provisional Bahamas clearance for OCU400 access pathway
Ocugen ($OCGN) received provisional approval and priority designation from the Bahamas’ Longevity and Regenerative Therapies Board for OCU400, its experimental gene therapy for retinitis pigmentosa. The company intends to supply the treatme ...
